Clinical Trial Update: Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) [Phase 4]

View source ↗

Summary

Phase 4 trial (MyRisk) comparing oral Akynzeo to standard of care for preventing chemotherapy-induced nausea and vomiting in high-risk MEC patients has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• Akynzeo (netupitant/palonosetron)

Snippet

Sponsor: Helsinn Healthcare SA | Conditions: Chemotherapy-induced Nausea and Vomiting | Phase 4 | Status: COMPLETED | Results posted: 2025-10-29